(S)-N-Methyl-(2-methyl-1-trifluoromethyl-propyl)-amine | 1349702-21-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (S)-N-Methyl-(2-methyl-1-trifluoromethyl-propyl)-amine
• 英文别名: (2S)-1,1,1-trifluoro-N,3-dimethylbutan-2-amine
• CAS: 1349702-21-1
• 化学式: C₆H₁₂F₃N
• 分子量: 155.16
• InChiKey: KJFAZMSMBYNUOV-YFKPBYRVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] PESTICIDAL AND PARASITICIDAL PYRAZOLE-ISOXAZOLINE COMPOUNDS<br/>[FR] COMPOSÉS DE PYRAZOLE-ISOXAZOLINE À ACTIVITÉ PESTICIDE ET PARASITICIDE
  申请人：MERIAL INC

  公开号：WO2019036407A1

  公开（公告）日：2019-02-21

  The present invention relates to pesticidal and parasiticidal isoxazoline of formula (I) and salts thereof: wherein variables R1, P, Y and Q are described herein are as defined in the description. The invention also relates to parasiticidal and pesticidal compositions comprising the isoxazoline compounds of formula (I), processes for their preparation and their uses to prevent or treat parasitic infections or infestations in animals and as pesticides.

  本发明涉及式(I)的杀虫剂和杀寄生虫的异恶唑啉及其盐：其中变量R1、P、Y和Q如本文所述，在描述中定义。本发明还涉及包含式(I)异恶唑啉化合物的杀寄生虫和杀虫组合物，其制备过程及其用于预防或治疗动物寄生虫感染或侵袭以及作为杀虫剂的应用。
• Compounds for inhibition of α4β7 integrin
  申请人：Gilead Sciences, Inc.

  公开号：US11179383B2

  公开（公告）日：2021-11-23

  The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.

  本公开提供了一种式 (I) 的化合物： 或其药学上可接受的盐。本公开还提供了包含式（I）化合物的药物组合物、制备式（I）化合物的工艺以及治疗炎症性疾病的治疗方法。
• INHIBITORS OF HEPATITIS C VIRUS
  申请人：Presidio Pharmaceuticals, Inc.

  公开号：EP2632261B1

  公开（公告）日：2016-07-13
• Compounds for Inhibition of Alpha 4 Beta 7 Integrin
  申请人：Gilead Sciences, Inc.

  公开号：US20200163953A1

  公开（公告）日：2020-05-28

  The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.
• IMIDAZOPYRIDINE DERIVATIVES
  申请人：Gilead Sciences, Inc.

  公开号：US20220135561A1

  公开（公告）日：2022-05-05

  The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.